Updated October 25, 2026 · Sources linked below

A treatment can sound persuasive long before researchers know whether it helps patients. Regenerative medicine aims to restore or replace damaged biological function, but the path from an interesting laboratory result to dependable care requires several kinds of evidence.

Laboratory success is a starting point

Experiments can clarify how cells behave or suggest a potential repair mechanism. Animal studies can explore additional questions. Neither automatically predicts a benefit in people with a particular condition.

Human studies then examine issues such as safety, appropriate treatment protocols, and clinical outcomes. Study design matters: a controlled comparison can help distinguish treatment effects from natural recovery, rehabilitation, or expectations.

The indication matters as much as the product

An actual approval illustrates the importance of specificity. FDA approved Ryoncil for a defined pediatric graft-versus-host disease indication. That decision does not establish efficacy for orthopedic pain, general rejuvenation, or a different cell preparation. [1]

Likewise, FDA says there are no approved exosome products. A clinic’s use of the term “regenerative” does not resolve that regulatory question. [2]

Read the outcome, not just the headline

“Repair” might mean a laboratory change, an imaging observation, reduced pain, or restored function. These are not identical. Ask whether the study measured something that matters to your daily life and whether the effect lasted.

FDA advises patients to question unapproved regenerative-medicine claims and explains that registration or listing alone does not establish approval. [3]

Questions for an evidence discussion

  • Is this established care, off-label use of an approved product, or an investigational product?
  • What controlled human evidence supports the proposed use?
  • Were complications and people who withdrew included in the report?
  • What would happen if I chose standard care or observation instead?

An honest explanation can be hopeful about scientific progress and precise about what is available today. Those are compatible positions.

Bring the evidence into your next conversation

Our patient guide to exosomes, stem cells and PRP compares the terms and provides six questions to bring to an appointment. You can also read Dan McCarthy, PA’s biography and learn about the OlympusMD team in Milton.

For questions about clinic services and appointments, call (470) 359-4815.

Sources and further reading

  1. FDA: Ryoncil approval for pediatric steroid-refractory acute graft-versus-host disease, December 18, 2024
  2. FDA: public safety alert on unapproved stem-cell and exosome products
  3. FDA: patient information about regenerative medicine therapies

Patient education from OlympusMD Wellness in Milton, Georgia. This article provides general information and does not replace an individual medical evaluation.